Peptides

Peptide H-SGAQASSTPLSPTR^-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-SGAQASSTPLSPTR^-OH include the following: Robust, reproducible and quantitative analysis of thousands of proteomes by micro-flow LC-MS/MS Y Bian , R Zheng , FP Bayer , C Wong, YC Chang - Nature , 2020 - nature.comhttps://www.nature.com/articles/s41467-019-13973-x 1DGE+ LC-MS/MS G Canx - researchgate.nethttps://www.researchgate.net/profile/Sebastien-Voisin/publication/235962738_2007_MCP_S1_Lawrence_Puente/data/0deec514d6336e8499000000/2006-Canada-3-MCP-S1-Puente.pdf

SARS-CoV-2 Spike RBD 395-430 peptide is an epitope of interest of the SARS-CoV-2 Spike S glycoprotein Receptor-Binding Domain (RBD). SARS-CoV-2 Spike RBD 395-430 peptide is useful for vaccine development and for structure-activity relationship studies SARS-CoV-2 Spike (S) glycoprotein Spike (S) glycoprotein corresponds to one of the leading targets for COVID-19 disease. Present on the surface of Sars-CoV-2 virus, Spike S protein is a class I fusion protein that allows the virus to enter host cells. With a 1 273 aa length, Spike protein has 2 subunits : S1 contains the receptor-binding domain RBD and S2 induces the fusion of the viral envelop with the cellular membrane. SARS-CoV-2 Spike RBD: The receptor-binding domain in SARS-CoV-2 Spike protein allows binding to the Angiotensin-Converting Enzyme receptor 2 (ACE2 receptor) which mediates the viral entry. SB-PEPTIDE also offers SARS-CoV-2 Spike RBD 395-430 (Biotin-LC) peptide

A synthetic peptide for use as a blocking control in assays to test for specificity of KCNQ1 antibody, catalog no. 70R-5042

Sarafotoxin S6b, sourced from the venom of the Atractaspis engaddensis snake family, is one of four (S6a-d) isopeptides of the Sarafotoxins. This product is a synthetically produced toxin, containing disulfide bonds between Cys1-Cys15 and Cys3-Cys11.Due to their structural and functional homology to the endothelin peptides, Sarafotoxins can enhance vasoconstriction through stimulating the class A G-protein-coupled, endothelin ETA and ETB receptors. This in turn leads to left ventricular dysfunction and bronchoconstriction. As the most potent Sarafotoxin, sarafotoxin S6b binds to both ETA and ETB receptors with a similar affinity to Endothelin-1. This is evident as when given to mice intravenously, sarafotoxin S6b caused cardiac arrest and death in mice almost immediately. Additional characteristics of S6b is its matrix metalloproteinase inhibitory activity due to it exhibiting a fold which is also found in the core region of tissue inhibitors of metalloproteinases (TIMPs). Sarafotoxin S6b can be used as a pharmacological reagent to study the interactions of Endothelins and their corresponding receptors. This product is available as a 0.1mg vial.

Custom research peptide; min purity 95%. For different specs please use the Peptide Quote Tool

A synthetic peptide for use as a blocking control in assays to test for specificity of TBC1D10A antibody, catalog no. 70R-10115

Gly-Gly-Gly-Gly-Arg-Gly-Asp-Ser-Pro is a peptide used as an activator in research. It can be used to study protein interactions and the effects of ligands on ion channels and receptors. Gly residues are able to form hydrogen bonds, which is why they are often used as spacers in proteins. This peptide has a high purity and CAS number.

Peptide H-AEEDEILNR^-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-AEEDEILNR^-OH include the following: Ultracentrifugation versus kit exosome isolation: nanoLC-MS and other tools reveal similar performance biomarkers, but also contaminations FS Skottvoll , HE Berg, K Bjorseth, K Lund - Future science , 2018 - Future Sciencehttps://www.future-science.com/doi/abs/10.4155/fsoa-2018-0088 Critical comparison of ultracentrifugation and a commercial kit for isolation of exosomes derived from glioblastoma and breast cancer cell lines FS Skottvoll , HE Berg, K Bjorseth, K Lund, N Roos - BioRxiv, 2018 - biorxiv.orghttps://www.biorxiv.org/content/10.1101/274910.abstract Bottom up proteomics data analysis strategies to explore protein modifications and genomic variants AS Carvalho , D Penque, R Matthiesen - Proteomics, 2015 - Wiley Online Libraryhttps://analyticalsciencejournals.onlinelibrary.wiley.com/doi/abs/10.1002/pmic.201400186 Selective and sensitive quantification of the cytochrome P450 3A4 protein in human liver homogenates through multiple reaction monitoring mass spectrometry A Cieślak , I Kelly, J Trottier, M Verreault, E Wunsch - , 2016 - Wiley Online Libraryhttps://analyticalsciencejournals.onlinelibrary.wiley.com/doi/abs/10.1002/pmic.201500386

EBVEBNA3B (416-424) is an HLA-A11-restricted antigenic peptide derived from the EBVEBNA3B protein.

Peptide H-TLTLFNVTR-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-TLTLFNVTR-OH include the following: Development of serum glycoproteomic profiling technique; simultaneous identification of glycosylation sites and site-specific quantification of glycan structure changes K Ueda , S Takami, N Saichi, Y Daigo - Molecular & Cellular , 2010 - ASBMBhttps://www.mcponline.org/article/S1535-9476(20)30899-9/fulltext

Peptide H-VNTLTER-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-VNTLTER-OH include the following: Reference antigen-free and antibody-free LTD-IDMS assay for influenza H7N9 vaccine in vitro potency determination K Morgenstern, Y Xie, G Palladino, JR Barr - Vaccine, 2018 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0264410X18312040 Immunocapture isotope dilution mass spectrometry in response to a pandemic influenza threat CL Pierce, TL Williams, WI Santana, M Levine - Vaccine, 2017 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0264410X1730957X Development of influenza A (H 7 N 9) candidate vaccine viruses with improved hemagglutinin antigen yield in eggs C Ridenour, A Johnson, E Winne - Influenza and other , 2015 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1111/irv.12322

A synthetic peptide for use as a blocking control in assays to test for specificity of SMPD2 antibody, catalog no. 70R-1809

A synthetic peptide for use as a blocking control in assays to test for specificity of PKM2 antibody, catalog no. 70R-9543

Neuromedin U Precursor-Related Peptide 36 (Rat, Mouse) is a peptide that belongs to the group of activator peptides. It is an inhibitor of ion channels and can be used as a research tool in cell biology and pharmacology. Neuromedin U Precursor-Related Peptide 36 (Rat, Mouse) has been shown to activate potassium channels and inhibit sodium currents. This peptide also interacts with receptors and ligands.

A synthetic peptide for use as a blocking control in assays to test for specificity of SF3A1 antibody, catalog no. 70R-4828

Peptide H-FTLSVDR^-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-FTLSVDR^-OH include the following: Development and validation of an LC-MS/MS method for simultaneous quantification of co-administered trastuzumab and pertuzumab S Schokker , F Fusetti, F Bonardi, RJ Molenaar - MAbs, 2020 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.1080/19420862.2020.1795492 Analytical and pharmacological consequences of the in vivo deamidation of trastuzumab and pertuzumab P Bults , A van der Voort, C Meijer, GS Sonke - Analytical and , 2022 - Springerhttps://link.springer.com/article/10.1007/s00216-021-03756-z Enrichment and Liquid Chromatography-Mass Spectrometry Analysis of Trastuzumab and Pertuzumab Using Affimer Reagents O Olaleye, B Spanov, R Ford, N Govorukhina - Analytical , 2021 - ACS Publicationshttps://pubs.acs.org/doi/abs/10.1021/acs.analchem.1c02807 Simultaneous quantification of co-administered trastuzumab and pertuzumab in serum based on nano-surface and molecular-orientation limited (nSMOL) proteolysis L Liu, B Sun, J Cai, J Wang, W Liu, H Hu, S Chen - RSC advances, 2024 - pubs.rsc.orghttps://pubs.rsc.org/en/content/articlehtml/2024/ra/d4ra03060e Method development and validation of LC-MS/MS-based assay for the simultaneous quantitation of trastuzumab and pertuzumab in cynomolgus monkey serum and L Gui, L Li, L Dong, S Xiang, J Zhai - Biomedical , 2020 - Wiley Online Libraryhttps://analyticalsciencejournals.onlinelibrary.wiley.com/doi/abs/10.1002/bmc.4903 Wolfgang Paul Lecture K Prather - dgms2024.dehttps://dgms2024.de/fileadmin/media/dgms/2024/docs/Abstractbooklet_DGMS_2024_final_1103.pdf Session 1: Proteomics Oral Presentation J Poehls, C Landerer, D Richter, A Shevchenko - dgms2024.dehttps://dgms2024.de/fileadmin/media/dgms/2024/docs/Abstracts_dgms2024_07032024.pdf Simultaneous quantification of trastuzumab and pertuzumab in human serum using accurate mass spectrometry EN Simon Roberts - sciex.comhttps://sciex.com/content/dam/SCIEX/pdf/tech-notes/biopharma/RUO-MKT-02-15248-A_Quant_of_mAb_therapeutics_in_combination_therapy_using_the_ZenoTOF_7600_system_RB_Final.pdf Mass Spectrometric ITEM-ONE and ITEM-TWO Analyses Confirm and Refine an Assembled Epitope of an Anti-Pertuzumab Affimer C Röwer, OO Olaleye, R Bischoff , MO Glocker - Biomolecules, 2023 - mdpi.comhttps://www.mdpi.com/2218-273X/14/1/24 Pertuzumab charge variant analysis and complementarity-determining region stability assessment to deamidation B Spanov, O Olaleye, T Mesurado - Analytical , 2023 - ACS Publicationshttps://pubs.acs.org/doi/abs/10.1021/acs.analchem.2c03275

A synthetic peptide for use as a blocking control in assays to test for specificity of RBMS1 antibody, catalog no. 70R-1625

Peptide NAP is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using NAP include the following: Neuroprotective peptide NAPVSIPQ antagonizes ethanol inhibition of L1 adhesion by promoting the dissociation of L1 and Ankyrin-G X Dou , JY Lee, ME Charness - Biological psychiatry, 2020 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0006322319316592 A pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alpha SM Fleming , CK Mulligan, F Richter, F Mortazavi - Molecular and Cellular , 2011 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S1044743110002745 VIP/PACAP-Based Drug Development: The ADNP/NAP-Derived Mirror Peptides SKIP and D-SKIP Exhibit Distinctive in vivo and in silico Effects S Sragovich, N Amram, A Yeheskel - Frontiers in Cellular , 2020 - frontiersin.orghttps://www.frontiersin.org/articles/10.3389/fncel.2019.00589/full The ADNP derived peptide, NAP modulates the tubulin pool: implication for neurotrophic and neuroprotective activities S Oz , Y Ivashko-Pachima, I Gozes - PloS one, 2012 - journals.plos.orghttps://journals.plos.org/plosone/article?id=10.1371/journal.pone.0051458 NAP, a femtomolar-acting peptide, protects the brain against ischemic injury by reducing apoptotic death RR Leker , A Teichner, N Grigoriadis, H Ovadia - Stroke, 2002 - Am Heart Assochttps://www.ahajournals.org/doi/abs/10.1161/01.STR.0000014207.05597.D7 The neuroprotective peptide NAP inhibits the aggregation of the beta-amyloid peptide O Ashur-Fabian , Y Segal-Ruder, E Skutelsky - Peptides, 2003 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0196978103002729 Activity-dependent neuroprotective protein (ADNP)-derived peptide (NAP) ameliorates hypobaric hypoxia induced oxidative stress in rat brain NK Sharma , NK Sethy , RN Meena, G Ilavazhagan - Peptides, 2011 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0196978111001215 Is NAP an additional neuroprotector in Alzheimer's disease? MH Yang, YL Chen, CY Lu, WC Tsai, YC Tyan - and Genomic Medicine, 2013 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S2214024713000622 Reduction of aluminum ion neurotoxicity through a small peptide application-NAP treatment of Alzheimer's disease MH Yang, SC Chen, YF Lin, YC Lee, MY Huang - Journal of Food and , 2019 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S1021949819300109 Differential effects of ethanol antagonism and neuroprotection in peptide fragment NAPVSIPQ prevention of ethanol-induced developmental toxicity MF Wilkemeyer, S Chen, CE Menkari - Proceedings of the , 2003 - National Acad Scienceshttps://www.pnas.org/doi/abs/10.1073/pnas.1331636100 Tubulin is the target binding site for NAP-related peptides: ADNF-9, D-NAP, and D-SAL M Holtser-Cochav, I Divinski, I Gozes - Journal of molecular neuroscience, 2006 - Springerhttps://link.springer.com/article/10.1385/JMN:28:3:303 Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide M Bassan, R Zamostiano, A Davidson - Journal of , 1999 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1046/j.1471-4159.1999.0721283.x A peptide derived from activity-dependent neuroprotective protein (ADNP) ameliorates injury response in closed head injury in mice L Beni-Adani , I Gozes , Y Cohen , Y Assaf - of Pharmacology and , 2001 - ASPEThttps://jpet.aspetjournals.org/content/296/1/57.short A novel peptide prevents death in enriched neuronal cultures I Zemlyak, S Furman, DE Brenneman, I Gozes - Regulatory peptides, 2000 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0167011500001981 Efficient intracellular delivery of nucleic acid pharmaceuticals using cell-penetrating peptides I Nakase, H Akita, K Kogure, A Graslund - Accounts of chemical , 2012 - ACS Publicationshttps://pubs.acs.org/doi/abs/10.1021/ar200256e NAP alpha-aminoisobutyric acid (IsoNAP) I Gozes , Y Schirer, A Idan-Feldman, M David - Journal of Molecular , 2014 - Springerhttps://link.springer.com/article/10.1007/s12031-013-0103-8 D-SAL and NAP: two peptides sharing a SIP domain I Gozes , S Sragovich, Y Schirer - Journal of Molecular , 2016 - Springerhttps://link.springer.com/article/10.1007/s12031-015-0701-8 A novel VIP responsive gene: activity dependent neuroprotective protein I Gozes , R Zamostiano, A Pinhasov - Annals of the New , 2000 - Wiley Online Libraryhttps://nyaspubs.onlinelibrary.wiley.com/doi/abs/10.1111/j.1749-6632.2000.tb06957.x From vasoactive intestinal peptide (VIP) through activity-dependent neuroprotective protein (ADNP) to NAP: a view of neuroprotection and cell division I Gozes , I Divinsky, I Pilzer, M Fridkin - Journal of Molecular , 2003 - Springerhttps://link.springer.com/article/10.1385/JMN:20:3:315 NAP and D-SAL: neuroprotection against the beta amyloid peptide (1-42) I Gozes , I Divinski, I Piltzer - BMC neuroscience, 2008 - Springerhttps://link.springer.com/article/10.1186/1471-2202-9-S3-S3 NAP: Research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP) I Gozes , BH Morimoto , J Tiong, A Fox - CNS drug , 2005 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1111/j.1527-3458.2005.tb00053.x Activity-dependent neuroprotective protein (ADNP)-derived peptide (NAP) counteracts UV-B radiation-induced ROS formation in corneal epithelium G Maugeri , AG D'Amico, S Giunta, C Giallongo - Antioxidants, 2022 - mdpi.comhttps://www.mdpi.com/2076-3921/11/1/128 NAP, a peptide derived from the activity-dependent neuroprotective protein, modulates macrophage function FJ Quintana , R Zaltzman - Annals of the New , 2006 - Wiley Online Libraryhttps://nyaspubs.onlinelibrary.wiley.com/doi/abs/10.1196/annals.1317.069 A novel iron-chelating derivative of the neuroprotective peptide NAPVSIPQ shows superior antioxidant and antineurodegenerative capabilities D Blat, L Weiner, MBH Youdim - Journal of medicinal , 2008 - ACS Publicationshttps://pubs.acs.org/doi/abs/10.1021/jm070800l The interaction of possible anti-AD ASA-NAP peptide conjugate with tubulin: A theoretical and experimental insight CS Mocanu, G Drochioiu - International Journal of Peptide Research and , 2021 - Springerhttps://link.springer.com/article/10.1007/s10989-021-10267-z FTIR and MS evidence for heavy metal binding to anti-amyloidal NAP-like peptides AV Lupaescu , M Jureschi, CI Ciobanu , L Ion - Journal of Peptide , 2019 - Springerhttps://link.springer.com/article/10.1007/s10989-018-9672-2 Direct evidence for binding of aluminum to NAP anti-amyloid peptide and its analogs AV Lupaescu , I Humelnicu , BA Petre - Journal of Mass , 2020 - journals.sagepub.comhttps://journals.sagepub.com/doi/abs/10.1177/1469066719877714 Zinc binding to NAP-type neuroprotective peptides: nuclear magnetic resonance studies and molecular modeling AV Lupaescu , CS Mocanu, G Drochioiu , CI Ciobanu - Pharmaceuticals, 2021 - mdpi.comhttps://www.mdpi.com/1424-8247/14/10/1011 Design and synthesis of new anti-amyloid NAP-based/like peptides AV Lupaescu , CI Ciobanu , I Humelnicu , BA Petre - Rev. Roum , 2019 - revroum.lew.rohttps://revroum.lew.ro/wp-content/uploads/2019/06/Art%2010.pdf